FDA Clears New Ultrasound Systems from Esaote
The MyLab A50 and MyLab A70 ultrasound platforms reportedly enable a variety of detailed and multiparametric evaluations, including assessments for liver elastography and strain analysis echocardiography.
The Food and Drug Administration has granted 510(k) clearance for the MyLab A50 and MyLab A70 ultrasound devices that combine advanced imaging and artificial intelligence (AI) capabilities to facilitate improved diagnostic precision.
Providing detailed assessment and multiparametric evaluations, the MyLab A50 and MyLab A70 ultrasound platforms facilitate attenuation imaging, liver elastography and cardiology applications such as strain analysis, according to Esaote, the manufacturer of the devices.
The newly FDA-cleared MyLab A50 and MyLab A70 (shown above) ultrasound devices emphasize high portability and a variety of advanced imaging applications. (Image courtesy of Esaote.)
Esaote added that the battery-operated compact design of the devices enable portability in a variety of clinical settings and ease of use for increased efficiency.
“The new A-series emphasizes user experience with a diverse range of interface options, including both a conventional and touch control panel. The devices boast an intuitive, easy-to-clean design that allows clinicians to operate efficiently and confidently,” noted Thomas Will, the director of ultrasound sales at Esaote North America.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
